Standout Papers

Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multice... 2023 2026 2024170
  1. Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial (2023)
    Juan P. Frías, Srikanth Deenadayalan et al. The Lancet

Immediate Impact

2 from Science/Nature 81 standout
Sub-graph 1 of 18

Citing Papers

Resveratrol for the Management of Human Health: How Far Have We Come? A Systematic Review of Resveratrol Clinical Trials to Highlight Gaps and Opportunities
2024 Standout
Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial
2024 Standout
3 intermediate papers

Works of Stanislava Macura being referenced

Efficacy and safety of once-weekly semaglutide 2·0 mg versus 1·0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial
2021

Author Peers

Author Last Decade Papers Cites
Stanislava Macura 324 147 134 9 386
Lalita Prasad‐Reddy 251 137 76 9 360
G. Kemmeries 360 138 88 6 441
Lisa Getty‐Kaushik 195 153 73 8 348
Wenying Huang 219 165 58 9 351
Silvia Ciani 284 187 58 5 388
Amalie R. Lanng 334 179 50 10 405
Riccardo Urbanet 252 42 167 11 441
Emma K. Biggs 253 170 78 7 444
Sayeh Tadayon 306 156 155 7 387
S. Isami 137 150 70 9 358

All Works

Loading papers...

Rankless by CCL
2026